Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

The transition from myelodysplastic neoplasm to secondary acute myeloid leukemia is revealed by molecular analysis, while functional drug screening demonstrates novel sensitivity patterns with clinical implication

View Full Paper
Ask AI
Bookmark
Share

Authors

JWJieya WuMAMichelle AfkhamiEJErlie Jiang

Discussion

Loading...

Member takes

Overview

Functional drug screening demonstrates specific treatment responses in patients transitioning from myelodysplastic neoplasm to secondary acute myeloid leukemia.

Key Points

  • Secondary acute myeloid leukemia transition showcases altered molecular patterns and drug sensitivity.
  • Mutation analysis revealed significant changes, with clonal evolution marking disease progression in patients.
  • Assessment using a high throughput drug screen enabled evaluation of up to 64 treatments across various drug classes.
  • Targets include effective agents for high-risk myelodysplastic neoplasm, signaling a potential shift in therapeutic approaches.

Cite This Study

Wu et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5dehttps://doi.org/10.1182/blood-2025-4328
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Multiomics-guided ex vivo drug sensitivity testing in Relapsed/Refractory Acute Myeloid Leukemia2025
  2. 2Molecular subclusters across the continuum of myelodysplastic neoplasms and acute myeloid leukaemia define distinct clinical entities2025
  3. 3Longitudinal genomic and cytogenetic dynamics in myelodysplastic syndromes (MDS): Insights into clonal evolution and disease progression2025
  4. 4Searching for a myelodysplastic syndrome stem cells (MDS-SCs) signature by flow cytometry: Toward a new prognostic tool?2025 · 1 citations
  5. 55-azacytidine treatment reshapes clonal structure and alters mutation-dependent splicing in MDS patients2025